HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors

Area of Science:

• Biochemistry
• Molecular Biology
• Enzymology

Background:

• Reverse transcriptase (RT) is crucial for viral replication and a target for antiviral therapies.
• Mutations in RT, such as Y181C, can confer resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs).
• Understanding the mechanistic basis of these mutations is vital for developing effective antiviral strategies.

Purpose of the Study:

• To elucidate the polymerization mechanism of the Y181C mutant reverse transcriptase.
• To investigate the impact of the Y181C mutation on nucleotide incorporation kinetics.
• To determine the mechanism of nonnucleoside inhibitor resistance conferred by the Y181C mutation.

Main Methods:

• Pre-steady-state kinetic techniques were employed to study enzyme mechanism.
• Binding affinities (Kd) for DNA and Nevirapine were measured for wild-type and Y181C mutant RT.
• Enzyme kinetics in the presence of Nevirapine were analyzed.

Main Results:

• The Y181C mutation alters nucleotide binding affinity but maintains a similar single nucleotide incorporation pathway to wild-type RT.
• The Y181C mutant enzyme exhibits a significantly reduced affinity for Nevirapine (approx. 500-fold increase in Kd).
• Nevirapine resistance is primarily due to a faster inhibitor dissociation rate from the Y181C mutant enzyme complex.

Conclusions:

• The Y181C mutation in reverse transcriptase modulates enzyme kinetics and confers resistance to Nevirapine.
• The findings provide mechanistic insights into NNRTI resistance, aiding in the design of next-generation antivirals.
• Further studies on inhibitor-enzyme interactions are warranted to overcome resistance mechanisms.